Search Results

Rarecells is thrilled to announce its breakthrough publication, written in partnership with the team of Dr. Azra Raza from Columbia University Irving Medical Center, revealing for the first time the presence of circulating giant cancer cells (CGCCs) in patients with Myelodysplastic Syndrome (MDS).

Rarecells, Inc. announced the appointment of Dr. Neil Gunn, a recognized leader and expert in the diagnostic space, as an independent Board Director.

Rarecells, Inc announced today the closing of a $5 Million tranche, bringing its total Series A funding to $13 Million.

Rarecells, Inc., a healthcare company in the field of liquid biopsy, focused on the development and commercialization of non-invasive tests for early cancer detection, announced that it has entered into an agreement with Columbia University to fund a clinical study evaluating its ISET® -AML test for early detection of acute myeloid leukemia in patients with myelodysplastic syndrome.

Akadeum Life Sciences and NanoCellect Biomedical enter a development and co-marketing collaboration to provide rapid and gentle rare-cell isolation. [10-June-2020] ANN ARBOR, Mich. , June 10, 2020 /PRNewswire/ -- Akadeum Life Sciences, Inc., creators of a next generation floatation-based isolation platform, and NanoCellect Biomedical, Inc., a leader in the development

Rarecells Diagnostics announces that the European Patent Office has nominated Professor Patrizia Paterlini-Bréchot, as one of the three finalists of the European Inventor Award 2019 - category “Research"- for developing ISET®, a new diagnostic blood test for cancer.

Rarecells Inc., a leading Liquid Biopsy company is pleased to announce the development of an innovative and accurate targeted digital single-cell Next-Generation Sequencing (scNGS) for single-nucleotide variant (SNV) method to detect mutant genes of pancreatic ductal adenocarcinoma (PDAC) circulating tumor cells (CTC)

Rarecells, Inc. (USA), a leading Liquid Biopsy company, is pleased to announce that National Institute of Integrative Medicine’s (Melbourne, Australia) researchers obtained striking results in a group of Australian men using the ISET® test for early prostate cancer diagnosis through the detection of Prostate-Specific Antigen (PSA) positive Circulating Tumor Cells (CTC).

Rarecells Diagnostics (France), a leading liquid biopsy company, is pleased to announce that the University Medical Center of Groningen, The Netherlands, has published research comparing the performance of the ISET® technology to the reference antibody-based system in Non-Small Cells Lung Cancer (NSCLC) demonstrating key advantages of the ISET® technology.